Care and A Cure
PEOPLE LIVING WITH ALS ARE AT THE CENTER OF EVERYTHING WE DO.

OUR MISSION
To empower people with Lou Gehrig’s Disease and their families to live fuller lives by providing compassionate care and support, and leading the fight to treat and cure ALS through global research and nationwide advocacy.
In the fiscal year ending Jan. 31, 2019, the Evergreen Chapter amassed $1,018,000 in total revenue, and had total expenses of $1,314,331. Expenditures included $1,050,959 for chapter programs; $208,060 for fundraising and $55,312 for administrative expenses. Net assets at year end were $462,855.
Be a Part of Events in 2019

**FURTHER OUR MISSION**

Help provide vital services to those living with ALS

---

**WALK TO DEFEND ALS**

- Anchorage – June 15
- Bellingham – Sept. 7
- Boise – Sept. 21
- Missoula – Sept. 14
- Pocatello – June 1
- Seattle – Sept. 14
- Spokane – April 27
- Tacoma – Sept. 28
- Tri-Cities – Sept. 28
- Yakima – Oct. 5

**WALK & ROLL TO DEFEAT ALS**

- Silver Valley – June 22

**STEP UP TO THE PLATE LUNCHEON**

- Seattle – May 3

**RIDE TO DEFEAT ALS**

- Treasure Valley – May 11
- Snohomish – June 29

**ALS WITH THE EXPERTS**

- Boise – June 8

---

Help provide vital services to those living with ALS

---

**KIF5A ALS GENE DISCOVERED**

A large collaborative effort involving over 250 researchers, led by Dr. John Landers (UMass Medical School) and Dr. Bryan Traynor (NIH), came together to achieve this exciting gene discovery, including organizations supported by the Association — Project MinE, Genomic Translation for ALS Care, Answer ALS, the Target ALS Postmortem Tissue Core, the New York Genome Center (NYGC) ALS Consortium, the CReAte Consortium, the NIH, and others.

**FDA DRUG APPROVED FOR ALS**

ITF Pharma, Inc. announced that Tigrutik*, the first and only thickened liquid form of riluzole, was approved by the FDA to treat ALS. This formulation should help individuals with swallowing difficulties.

*Not funded by The ALS Association

**ANTISENSE DRUGS ACHIEVED SIGNIFICANT PROGRESS**

Biogen announced encouraging results of SOD1 (BIIB067) phase I trial and is moving to the next clinical phase with urgency. Biogen also initiated the C9orf72 (BIIB078) phase I trial this fall and the first patients were dosed.
I’m Honored to Join You

By Pauline Proulx, Executive Director

It is truly an honor to join you as the Executive Director of the ALS Association Evergreen Chapter. I am excited to get to know the ALS community as we work to provide much-needed services to patients and their families.

I have spent more than two decades working with non-profit organizations, in communications, operations and fundraising roles. Most recently, I was the Director for Services and Development at the Washington State Medical Association, where I led a team of association professionals that managed the operations, education and business for a variety of specialty-medicine groups.

I am grateful to my predecessor Becky Moore who led the organization as Executive Director for 19 years for her dedication to the chapter. Under Becky’s leadership in 2018, the Evergreen Chapter served almost 850 patients in Washington, Idaho, Montana and Alaska; we loaned more than 1,000 pieces of free medical equipment to patients and families throughout our region; our care coordinators provided more than 1,000 face-to-face, personalized visits; and our support groups attracted almost 1,500 participants.

Looking ahead, the Evergreen Chapter has its work cut out for us: Our patient population is growing; our Chapter’s region is the largest in the nation; our geographical identity includes both very urban and very rural regions; and our fundraising dollars are stretched more than ever. That said, I’m confident that we can rise to these challenges. I’m so grateful to people like you, whose commitment make this work possible.

I hope you’ll continue to stay engaged and support us. I look forward to meeting you!

Pauline Proulx
Pauline@alsa-ec.org